HSP70 IN THE DEVELOPMENT OF EXPERIMENTAL TOXIC HEPATITIS
DOI:
https://doi.org/10.5281/zenodo.18712137Keywords:
drug-induced liver injury; HSP70; hepatotoxicity; cellular stress response.Abstract
The relevance of drug-induced liver injury (DILI) lies in the fact that it remains one of the most challenging problems in clinical hepatology. It develops against the background of the widespread use of potentially hepatotoxic medications, polypharmacy, self-medication, and the concomitant intake of herbal remedies and dietary supplements. Although the overall population incidence of DILI is relatively low, it is one of the leading causes of acute liver failure and may be associated with high mortality, particularly in cases of delayed withdrawal of the causative agent and severe injury phenotypes.
References
Allison R.D., Fontana R.J. Drug induced liver injury: clinical perspectives and future directions // Hepatology Communications. — 2023. — Vol. 7, No. 2. — P. e1023–e1035. — DOI: 10.1002/hep4.2101
Björnsson E.S. Epidemiology and risk factors for drug-induced liver injury // Clinical Liver Disease. — 2022. — Vol. 19, No. 1. — P. 9–15. — DOI: 10.1002/cld.1187
Fontana R.J., Seeff L.B. Drug-induced liver injury: pathogenesis, diagnosis and management // Gastroenterology. — 2023. — Vol. 164, No. 4. — P. 1056–1072. — DOI: 10.1053/j.gastro.2022.12.045
Hosack T., Lumley M., Björnsson E. Drug-induced liver injury: a comprehensive review of current practice // World Journal of Gastroenterology. — 2023. — Vol. 29, No. 12. — P. 1821–1844. — DOI: 10.3748/wjg.v29.i12.1821
Teschke R., Danan G. Drug-induced liver injury: importance of causality assessment using RUCAM // Journal of Clinical and Translational Hepatology. — 2021. — Vol. 9, No. 3. — P. 393–403. — DOI: 10.14218/JCTH.2020.00109
